These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 9568811

  • 1. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Delgrange E, Crabbé J, Donckier J.
    Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
    [Abstract] [Full Text] [Related]

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T, Arikan E, Tasan E, Hatemi H.
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V, Freneau E, Morange I, Simonetta C.
    Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
    [Abstract] [Full Text] [Related]

  • 5. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 6. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B, Nesher Y, Barziliai S.
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [Abstract] [Full Text] [Related]

  • 7. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P.
    Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E, Camanni F.
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [Abstract] [Full Text] [Related]

  • 9. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P, Molitch ME.
    Endocr Pract; 2011 Jun; 17(3):e55-8. PubMed ID: 21324816
    [Abstract] [Full Text] [Related]

  • 10. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
    Eroukhmanoff J, Tejedor I, Potorac I, Cuny T, Bonneville JF, Dufour H, Weryha G, Beckers A, Touraine P, Brue T, Castinetti F.
    Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
    [Abstract] [Full Text] [Related]

  • 11. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ, Meacham LR.
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [Abstract] [Full Text] [Related]

  • 12. Dopamine receptor agonists for treating prolactinomas.
    Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G.
    Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
    [Abstract] [Full Text] [Related]

  • 13. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [Abstract] [Full Text] [Related]

  • 14. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Delgrange E, Donckier J.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2755-6. PubMed ID: 9253367
    [No Abstract] [Full Text] [Related]

  • 15. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [Abstract] [Full Text] [Related]

  • 16. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Colao A, Lombardi G.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2756. PubMed ID: 9253368
    [No Abstract] [Full Text] [Related]

  • 17. Hyperprolactinemia: pathophysiology and management.
    Verhelst J, Abs R.
    Treat Endocrinol; 2003 Aug; 2(1):23-32. PubMed ID: 15871552
    [Abstract] [Full Text] [Related]

  • 18. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
    Tng EL, Teo AE, Aung AT.
    J Med Case Rep; 2023 Mar 17; 17(1):96. PubMed ID: 36927797
    [Abstract] [Full Text] [Related]

  • 19. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar 17; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ, Brownell J, Lamberts SW.
    J Clin Endocrinol Metab; 1991 May 17; 72(5):1136-41. PubMed ID: 1673685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.